Ability Biologics secures US $6M seed extension financing - Private Capital Journal
Summary
Its powerful AbiLeap discovery engine combines massively parallel, continuously learning AI with an extensive database of antigen-antibody interactions to generate fully human, IgG-based multi-specific antibodies of exquisite selectivity and affinity.Ability Biologics Announces the Closing of its US $18 Million Seed Funding Extension toward the Generation of Novel, Highly Targeted ImmunomodulatorsMONTREAL, June 18, 2024 /CNW/ Ability Biologics (Ability) announced the final closing of its seed funding, raising a total of $18 million (US), a financing round led by founding investor Amplitude Ventures (Amplitude). Harnessing the latest technologies, like artificial intelligence, in the development of antibodies will solidify Qu\xe9becs expertise in an area that is critical to the treatment of various types of cancer, and ultimately other diseases, that affect many Quebecers every year.Ability Biologics is the premier cell targeting company. Its powerful AbiLeap discovery engine combines massively parallel, continuously learning AI with an extensive database of antigen-antibody interactions to generate fully human, IgG-based multi-specific antibodies of exquisite selectivity and affinity. Learn more about Amplitude and its Pre-Amp venture studio at amplitudevc.com.The Fonds de solidarit\xe9 FTQ is a source of pride in Qu\xe9bec, fulfilling its mission through a unique business model created 40 years ago. With net assets of $18.9 billion as at November 31, 2023, the Fonds supports more than 3,700 companies through venture and development capital investments based on the belief that impact is created as much by financial as social returns.